KR20230069984A - Tyk2 억제제 및 그의 용도 - Google Patents
Tyk2 억제제 및 그의 용도 Download PDFInfo
- Publication number
- KR20230069984A KR20230069984A KR1020237012767A KR20237012767A KR20230069984A KR 20230069984 A KR20230069984 A KR 20230069984A KR 1020237012767 A KR1020237012767 A KR 1020237012767A KR 20237012767 A KR20237012767 A KR 20237012767A KR 20230069984 A KR20230069984 A KR 20230069984A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutically acceptable
- solvate
- stereoisomer
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079217P | 2020-09-16 | 2020-09-16 | |
| US63/079,217 | 2020-09-16 | ||
| PCT/US2021/050649 WO2022060973A1 (en) | 2020-09-16 | 2021-09-16 | Tyk2 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230069984A true KR20230069984A (ko) | 2023-05-19 |
Family
ID=78086111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237012767A Pending KR20230069984A (ko) | 2020-09-16 | 2021-09-16 | Tyk2 억제제 및 그의 용도 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12679850B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4214215A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7824938B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230069984A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117279922B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021345181A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3192621A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301385A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022060973A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| CN119487037A (zh) * | 2022-03-16 | 2025-02-18 | 阿鲁米斯股份有限公司 | Tyk2抑制剂及其用途 |
| EP4493281A1 (en) * | 2022-03-16 | 2025-01-22 | Alumis Inc. | Tyk2 inhibitors and uses thereof |
| WO2023208244A1 (zh) * | 2022-04-29 | 2023-11-02 | 南京明德新药研发有限公司 | 大环类化合物及其应用 |
| EP4692096A4 (en) | 2023-03-31 | 2026-07-22 | Prime Gene Therapeutics Co Ltd | MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND ITS USE |
| WO2024222807A1 (en) * | 2023-04-27 | 2024-10-31 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Novel macrocyclic heteroaryl derivatives as kinase inhibitors |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1351691A4 (en) | 2000-12-12 | 2005-06-22 | Cytovia Inc | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF |
| AU2003262642B2 (en) | 2002-08-14 | 2010-06-17 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| US20060281763A1 (en) | 2005-03-25 | 2006-12-14 | Axon Jonathan R | Carboxamide inhibitors of TGFbeta |
| US7517882B2 (en) | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
| KR20100132550A (ko) | 2008-04-16 | 2010-12-17 | 포톨라 파마슈티컬스, 인코포레이티드 | syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드 |
| EP2361902A4 (en) | 2008-11-21 | 2012-04-25 | Astellas Pharma Inc | 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG |
| MX2011011875A (es) | 2009-05-08 | 2011-12-08 | Astellas Pharma Inc | Compuesto de carboxamida heterociclica diamino. |
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| EP2975027A1 (en) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
| AU2011323484B2 (en) | 2010-11-01 | 2016-10-06 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as Syk modulators |
| CN102250065B (zh) | 2011-05-20 | 2015-05-13 | 浙江海正药业股份有限公司 | 取代的三嗪苯脲衍生物及其用途 |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| PT2760453T (pt) | 2011-09-30 | 2016-08-02 | Ipsen Pharma Sas | Inibidores macrocíclicos da cinase lrrk2 |
| KR20140108594A (ko) | 2012-01-10 | 2014-09-11 | 에프. 호프만-라 로슈 아게 | 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도 |
| HRP20220766T1 (hr) | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| US9701689B2 (en) | 2012-11-30 | 2017-07-11 | Kyowa Hakko Kirin Co., Ltd. | Substituted pyridines and pyridazines as CCR10 receptor inhibitors |
| WO2014140299A1 (en) | 2013-03-15 | 2014-09-18 | Oncodesign S.A | Macrocyclic rip2 kinase inhibitors |
| JP6484555B2 (ja) | 2013-08-29 | 2019-03-13 | 京都薬品工業株式会社 | 新規芳香族化合物およびその用途 |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| AU2014360446A1 (en) | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
| WO2015112806A2 (en) | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| WO2015123453A1 (en) | 2014-02-14 | 2015-08-20 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as jak inhibitors |
| CN105111151B (zh) | 2015-04-17 | 2018-09-28 | 成都理工大学 | 作为PPAR-γ调节剂的氨基嘧啶衍生物 |
| BR112017025986A2 (pt) | 2015-06-02 | 2018-08-14 | Pharmacyclics Llc | inibidores de tirosina quinase de bruton. |
| RU2732405C2 (ru) | 2015-07-02 | 2020-09-16 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ |
| BR112018000297A2 (pt) | 2015-07-06 | 2018-09-04 | Tp Therapeutics Inc | polimorfo de macrociclo de diarila |
| WO2017015367A1 (en) | 2015-07-21 | 2017-01-26 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| KR102782807B1 (ko) * | 2015-11-18 | 2025-03-14 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
| EP3405464B1 (en) | 2016-01-22 | 2019-12-04 | Janssen Pharmaceutica NV | New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| AU2017302019A1 (en) | 2016-07-28 | 2019-02-07 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| US10836770B2 (en) * | 2016-10-07 | 2020-11-17 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018112027A1 (en) | 2016-12-14 | 2018-06-21 | Development Center For Biotechnology | Antibody-drug conjugates and uses thereof |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| CN106866660B (zh) | 2017-02-15 | 2019-05-17 | 上海天马有机发光显示技术有限公司 | 电子传输材料、包含其的oled显示面板和电子设备 |
| AU2018230737B2 (en) | 2017-03-08 | 2022-09-22 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors, uses, and methods for production thereof |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018186366A1 (ja) | 2017-04-03 | 2018-10-11 | 京都薬品工業株式会社 | 新規サイクリン依存性キナーゼ8及び/又は19阻害剤 |
| WO2018234345A1 (en) | 2017-06-21 | 2018-12-27 | F. Hoffmann-La Roche Ag | PYRAZOLO [1,5A] PYRIMIDINE DERIVATIVES AS MODULATORS OF IRAK4 |
| PT3658148T (pt) | 2017-07-28 | 2024-08-26 | Turning Point Therapeutics Inc | Compostos macrocíclicos e utilizações dos mesmos |
| US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
| KR102619444B1 (ko) | 2017-08-23 | 2023-12-29 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 아미노피라졸 및 피리미딘을 함유하는 마크로사이클 및 그의 약학적 조성물 및 용도 |
| WO2019049891A1 (ja) | 2017-09-06 | 2019-03-14 | 小野薬品工業株式会社 | Trk阻害剤とキナーゼ阻害剤の併用による癌治療方法 |
| CA3080157A1 (en) | 2017-10-26 | 2019-05-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| WO2019084499A1 (en) | 2017-10-27 | 2019-05-02 | Genea Biocells USA (Holdings), Inc. | INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION |
| CA3081790C (en) | 2017-11-10 | 2023-03-07 | Angex Pharmaceutical, Inc. | Macrocyclic compounds as trk kinase inhibitors and uses thereof |
| RS63787B1 (sr) | 2017-12-19 | 2022-12-30 | Turning Point Therapeutics Inc | Makrociklična jedinjenja za lečenje bolesti |
| WO2019144885A1 (zh) | 2018-01-23 | 2019-08-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑并[1,5-a]嘧啶类的大环化合物 |
| WO2019165967A1 (zh) | 2018-02-28 | 2019-09-06 | 南京明德新药研发有限公司 | 吡唑并嘧啶衍生物及其用途 |
| EP3773725A1 (en) | 2018-03-29 | 2021-02-17 | Loxo Oncology Inc. | Treatment of trk-associated cancers |
| CN109053682B (zh) | 2018-07-27 | 2020-10-27 | 东南大学 | 一种tdo小分子抑制剂衍生物及其抗肿瘤偶联物和制备方法 |
| RS66346B1 (sr) | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
| CA3126034A1 (en) * | 2019-01-23 | 2020-07-30 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| KR102943760B1 (ko) | 2019-01-28 | 2026-03-26 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 피리다진 유도체 억제제, 및 그의 제조 방법 및 용도 |
| SG11202108619SA (en) | 2019-02-07 | 2021-09-29 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| US20220177486A1 (en) | 2019-03-11 | 2022-06-09 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| SG11202110523XA (en) | 2019-03-26 | 2021-10-28 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| CN114929226B (zh) | 2019-11-08 | 2024-09-27 | 温缇克斯生物科学公司 | Tyk2假激酶配体 |
| EP4493281A1 (en) * | 2022-03-16 | 2025-01-22 | Alumis Inc. | Tyk2 inhibitors and uses thereof |
-
2021
- 2021-09-16 IL IL301385A patent/IL301385A/en unknown
- 2021-09-16 AU AU2021345181A patent/AU2021345181A1/en active Pending
- 2021-09-16 WO PCT/US2021/050649 patent/WO2022060973A1/en not_active Ceased
- 2021-09-16 JP JP2023517268A patent/JP7824938B2/ja active Active
- 2021-09-16 KR KR1020237012767A patent/KR20230069984A/ko active Pending
- 2021-09-16 EP EP21789976.4A patent/EP4214215A1/en active Pending
- 2021-09-16 CN CN202180076687.5A patent/CN117279922B/zh active Active
- 2021-09-16 US US18/026,309 patent/US12679850B2/en active Active
- 2021-09-16 CA CA3192621A patent/CA3192621A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021345181A1 (en) | 2023-05-04 |
| JP2023541203A (ja) | 2023-09-28 |
| US20230357273A1 (en) | 2023-11-09 |
| IL301385A (en) | 2023-05-01 |
| WO2022060973A1 (en) | 2022-03-24 |
| EP4214215A1 (en) | 2023-07-26 |
| CA3192621A1 (en) | 2022-03-24 |
| CN117279922A (zh) | 2023-12-22 |
| US12679850B2 (en) | 2026-07-14 |
| JP7824938B2 (ja) | 2026-03-05 |
| AU2021345181A9 (en) | 2024-06-20 |
| CN117279922B (zh) | 2025-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12351572B2 (en) | Substituted 1,2,4-triazoles as TYK2 inhibitors | |
| JP7824938B2 (ja) | Tyk2阻害剤およびその使用 | |
| KR102899985B1 (ko) | Tyk2 억제제 및 그의 용도 | |
| KR20240162539A (ko) | Tyk2 억제제 및 그의 용도 | |
| JP2025509594A (ja) | Tyk2阻害剤およびその使用 | |
| HK40105557B (en) | Tyk2 inhibitors and uses thereof | |
| HK40105557A (en) | Tyk2 inhibitors and uses thereof | |
| HK40120037B (en) | Tyk2 inhibitors and uses thereof | |
| HK40119624A (en) | Tyk2 inhibitors and uses thereof | |
| HK40119624B (en) | Tyk2 inhibitors and uses thereof | |
| HK40120037A (en) | Tyk2 inhibitors and uses thereof | |
| HK40065275A (zh) | Tyk2抑制剂和其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |